PAMETNA HRVATSKA Marko Bošković, powered by JANAF

Guest Marko BoškovićHosted by Boris ŽivkovićMay 3, 2026

Marko Bošković

About this episode

What you'll hear in this conversation

For patients on multiple medications, particularly those over sixty, the real danger isn't just one drug, but how all of them interact. These interactions are often subtle, affecting how drugs metabolize and creating unseen risks that even experienced doctors struggle to track. Marko Bošković, founder of Sanitas Analitica, saw this systemic gap and built an algorithm to address it. His company's core product, Polyparium Solutions, moves beyond general drug information to offer personalized insights. It scans a patient's entire drug regimen, predicts potential interactions — from drug-disease conflicts to metabolic overloads — and then suggests safer alternatives for new prescriptions. This isn't just about preventing side effects; it's about giving doctors a clearer view into a patient's future with their medication. This conversation reveals how a granular understanding of pharmacokinetic processes can redefine medical decision-making, shifting from generalized knowledge to patient-specific precision. It also explores the practical challenges of integrating such a system into existing hospital infrastructure, and what it takes to build a product that can truly augment clinical judgment.

Insights from the conversation

What to take from this episode

Most existing drug information tools focus on pairwise drug interactions. Marko Bošković's Polyparium Solutions algorithm, however, scans entire drug regimens of ten, fifteen, or twenty medications simultaneously. If your solution only handles combinations, it's missing the systemic risk that arises when many drugs interact at once.

Bošković describes drug metabolism pathways in the liver as 'toll booths on a highway' where drugs can cause 'traffic jams' if too many use the same route. The challenge isn't just knowing what a drug does, but how it's processed; building a functional model of complex biological systems allows you to predict consequences before they happen, rather than just reacting to symptoms.

While the Polyparium Solutions web application is complete and in use, Bošković's ultimate goal is to offer it as a plugin for existing Electronic Health Records (EHR) systems. Building a superior tool isn't enough; if doctors have to switch between different software, even the best solution will see low adoption. The path to adoption often means becoming invisible within the tools already in use.

Bošković differentiates his product from others by stating that they offer 'encyclopedic knowledge' while Polyparium provides 'personalized results' based on that specific patient. General knowledge is a commodity; specific, patient-centric insights are what create a new category of value in complex fields like medicine.

During closed beta testing, Bošković observed that the tool 'was shared quite a bit outside the closed beta test' by medical professionals. The most reliable signal of a product's utility isn't just positive feedback, but unsolicited sharing; if users are bypassing formal channels to get your tool into more hands, it means you've built something genuinely useful, not just something they're polite about.

Though current efforts focus on doctors and pharmacists, Sanitas Analitica plans a mobile application 'focused on patients,' noting that 'for patients, the offering is quite weak.' The same core insight can serve multiple user groups, but each needs a tailored interface and value proposition, and identifying a neglected user segment for a proven clinical tool opens a new market.

The company performed 'clinical validation' by studying 'patient workflow' at the Institute for Clinical and Experimental Medicine in Prague and smaller clinics in Croatia. True validation isn't just about proving efficacy in a lab; it's about observing how the tool fits into the actual, messy process of patient care. Understanding where your tool 'sits' in the daily routine is as important as its technical capabilities.

Marko Bošković's path began with medical studies and research where his mentor, Professor Robert Likić, 'constantly pushed' him 'in directions toward the digitalization of research.' The most impactful ventures often arise from a mentor's guidance and a sustained exposure to a problem space, rather than a sudden flash of inspiration.

Explore further

ScenariosBusiness challenges CardsEducational cards TimelineTopic evolution